What Leqembi’s New Device Could Mean for You
If you’ve ever helped a loved one get to a medical appointment, you know the day can feel long before it even begins.
You plan the drive, leave early, only to sit in traffic. Next, you check in at the office and wait. Then you might wait some more. By the time you get home, a visit can take up much of the day.
For many families who have loved ones being treated with one of the two FDA-approved Alzheimer’s medications (lecanemab or donanemab), these appointments become part of the week’s choreography. With the IV infusions taking anywhere from 90 minutes to 2 hours, it takes time, energy, and finding the room in a schedule that may already feel very full.
That’s why a new update about Leqembi (lecanemab) is getting deserved attention.
At the end of January 2026, drugmakers Eisai and Biogen announced that the U.S. Food and Drug Administration (FDA) accepted an application to allow some patients to begin using Leqembi Iqlik (pronounced lekembee ihclick). Patients won’t wait until the initial rounds of infusions are completed to use the autoinjector.
A Quick Refresher on Leqembi
Leqembi is a medication for early-stage Alzheimer’s disease. This includes people in the mild cognitive impairment or mild dementia stages. It drew national attention after a large clinical trial found that people who received lecanemab over an 18-month period declined slower than those who received a placebo.
While Leqembi is not a cure for Alzheimer’s and does not restore memory to what it once was, it may help slow cognitive decline for some people in the early stage of the disease.
Until recently, the default Leqembi treatment has been IV infusion. That means traveling to a clinic or infusion center, checking in, receiving the drug through an IV, and staying for monitoring. For many older adults and care partners, that schedule can be physically and emotionally demanding.
In August 2025, the FDA approved Leqembi Iqlik for weekly at-home maintenance dosing after a person had already completed 18 months of IV treatment in a clinic or infusion center.
(If the word autoinjector feels unfamiliar, it may help to picture an injection pen like the kind used for Epi-pens and diabetes or GLP-1 weight loss medications.)
The new January 2026 application goes further. It asked the FDA to allow more flexibility from the beginning: a starting dose that could be given at home and continued for ongoing treatment.
Expected in late May or early June 2026, the FDA’s decision means more families could soon decide where and how to take their Alzheimer’s medication.
Is It Easy to Use the Leqembi Injector at Home?
According to Eisai, the autoinjector has been tested with early stage Alzheimer’s patients, care partners, and health professionals to see how well it can be used at home.
In testing, nearly all participants were able to successfully give themselves the dose at home. People also reported that it was easy to use and appreciated the shorter treatment time, as well as the chance to avoid infusion center visits.
The early usability findings are promising, and they suggest that many families may be able to use the device successfully at home with the right training and support.
Just as important, the at-home option would still come with ongoing medical guidance. Patients would continue to have screening, counseling, MRI monitoring, and regular follow-up with their care team. The setting may change, but the support stays in place.
Why Families Are Taking Notice of Leqembi Iqlik
A lot of Alzheimer’s care happens outside the exam room.
You feel it in the drive from your house across town, the time in the waiting room, the reshuffled plans, and the constant coordination among family members trying to make it all work. One appointment can take up a big chunk of your day.
If approved, an at-home injector could reduce some of the time and strain that may come with repeated infusion visits. For patients and care partners, that could make treatment feel more manageable.
Progress That Feels Personal
We’ll be watching to see what the FDA decides. If approved for at-home starting doses, Leqembi Iqlik could mean treatment that fits a little more naturally into the week for patients and the people who show up for them.
There are names behind every breakthrough like this. People who signed up for a clinical trial, showed up for every visit, and put their trust in us. Charter Research patient volunteers were part of the clinical trial work that helped bring lecanemab to where it is today. That’s not a small thing. When a new medication is available, the people who took part in that research can see the impact of their contribution.
And the work continues. There are researchers and patient volunteers right now helping to advance the next generation of treatments. Someday, someone may read an article just like this one because of what they chose to do.
If you have questions about memory changes, would like a free memory screening, or want to learn about open clinical trials, we’re here to help.
Orlando: 407-337-3000
The Villages: 352-441-2000
Chicago: 773-300-1000